Torsemide versus Furosemide in the Treatment of Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Abstract

Furosemide is the most used diuretic for volume overload symptoms in patients with heart failure (HF). Recent data suggested that torsemide may be superior to furosemide in this setting. However, whether this translates into better clinical outcomes in this population remains unclear.

To assess whether torsemide is superior to furosemide in the setting of HF.

We performed a systematic review and meta-analysis of RCTs comparing the efficacy of torsemide versus furosemide in patients with HF. PubMed, Embase, and Web of Science were searched for eligible trials. Outcomes of interest were all-cause hospitalizations, hospitalizations for HF (HHF), hospitalizations for all cardiovascular causes, all-cause mortality, and NYHA class improvement. Echocardiographic parameters were also assessed. We applied a random-effects model to calculate risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) and a 0.05 level of significance.

12 RCTs were included, comprising 4,115 patients. Torsemide significantly reduced HHF (RR 0.60; 95% CI, 0.43-0.83; p=0.002; I²=0%), hospitalization for cardiovascular causes (RR 0.72; 95% CI, 0.60-0.88; p=0.0009; I²=0%), and improved LVEF (MD 4.51%; 95% CI, 2.94 to 6.07; p<0.0001; I²=0%) compared with furosemide. There was no significant difference in all-cause hospitalizations (RR 0.93; 95% CI, 0.86-1.00; p=0.04; I²=0%), all-cause mortality (RR 0.98; 95% CI, 0.87-1.10; p=0.73; I²=0%), NYHA class improvement (RR 1.25; 95% CI, 0.92-1.68; p=0.15; I²=0%), or NYHA class change (MD -0.04; 95% CI, -0.24 to 0.16; p=0.70; I²=15%) between groups.

Torsemide significantly reduced hospitalizations for HF and cardiovascular causes, also improving LVEF.

Keywords
Heart Failure; Sodium Potassium Chloride Symporter Inhibitors; Furosemide